Search

everythinglearnresearchcommunity

for

Search:↓

Ustekinumab significantly improved sexual function and quality of life for people with moderate to severe psoriasis.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

Topical ruxolitinib quickly improves non-segmental vitiligo.

Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.

Hydroxychloroquine showed some potential, but overall, the three drugs had limited success in treating lupus in dogs.

Oral tofacitinib successfully treated total body hair loss in one patient.

Tofacitinib treatment for hair loss may worsen acne.

Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

Alefacept does not effectively treat severe alopecia areata.

Tofacitinib, a hair regrowth treatment, may worsen acne.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

Semaglutide may help some skin disorders but can also cause skin issues.

A patient with complete hair loss regrew all her hair using tofacitinib.

A man developed facial skin lesions after a stem cell transplant, which improved with specific treatments.

Topical ruxolitinib cream may help treat frontal fibrosing alopecia.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.

Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.

Reducing immunosuppression and using antiviral creams improved the woman's skin condition.

Adalimumab can cause complete hair loss in rare cases.

Shrinking of oil glands in the skin is a key sign of hair loss linked to TNF inhibitor drugs and may improve if the treatment is stopped.

A patient with lupus experienced a condition where their immune cells became overactive.

Oral etretinate improved hair length and reduced beading in monilethrix.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.

JAK inhibitors offer new hope for treating severe alopecia areata.

Biologics for severe asthma have known side effects, but some new risks need more study.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.